Selected References:

  • Cohen LS, et al. 2018. Risk of major malformations in infants following first trimester exposure to quetiapine. Am J Psychiatry; 175:1225–1231
  • Damkier, P, & Videbech, P. 2018. The safety of second‐generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs; 32: 351– 66.
  • Ennis, Z. N., & Damkier, P. 2015. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformations. A Systematic Review. Basic Clin Pharmacol Toxicol, 116:315-320
  • FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: https://www.fda.gov/drugs/drugsafety/ucm243903.htm
  • Holt RI, Peveler RC. 2011. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf); 74(2):141-7.
  • Levesque, S. & Riley, C. 2017. Fetal exposure to lamotrigine and quetiapine in two consecutive pregnancies. Arch Womens Ment Health; 20:237-39.
  • Lusskin SI, et al. 2004. Prolactin elevation with ziprasidone, Am J Psychiatry; 161:1925.
  • National Institute of Health, U.S. Library of Medicine. 2018. Quetiapine. Retrieved from https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/f?./temp/~gppRYM:1
  • Peng M, et al. 2013. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology; 228:577–84.
  • Shao P, et al. 2015. Effects of Clozapine and other Atypical antipsychotics on infants development who were exposed to as fetus: A post-hoc analysis. PLoS One; 10(4):e0123373.
  • Sørensen MJ, et al. 2015. Risk of fetal death after treatment with antipsychotic medications during pregnancy. PLoS One; 10:e0132280.
  • Wichman CL. 2009. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health; 12:53–7.